In PC3-AGS22 cells stably expressing Nectin-4, the biological activity of the mutated ADC was similar to the un-mutated drug, indicating that Mu-anti-Nectin4-VcMMAE retained the targeted anti-tumor activity but ocular toxicity was reduced. Here, NECTIN4 is linked to neoplasm.